Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and β2-microglobulin in multiple myeloma

European Journal of Haematology

Volumn 70, Issue 1, 2003, Pages 34-42

  Terpos, Evangelos ^a   Viniou, Nora ^b   De La Fuente, Josu ^a   Meletis, John ^b   Voskaridou, Ersi ^b   Karkantaris, Christos ^c   Vaiopoulos, George ^b   Palermos, John ^c   Yataganas, Xenophon ^b   Goldman, John M ^a   Rahemtulla, Amin ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c 251 GENERAL AIR FORCE HOSPITAL   (Greece)

Author keywords

Bone markers; Ibandronate; Multiple myeloma; N terminal cross linking telopeptide of type I collagen (NTX); Pamidronate; Tartrate resistant acid phosphatase type 5b (TRACP 5b)

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA INTERFERON; BETA 2 MICROGLOBULIN; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; IBANDRONIC ACID; INTERLEUKIN 6; MARKER; OSTEOCALCIN; PAMIDRONIC ACID; PARAPROTEIN;

ADULT; AGED; ARTICLE; BONE RADIOGRAPHY; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG ACTIVITY; FEMALE; HUMAN; HYPERCALCEMIA; MALE; MULTIPLE MYELOMA; OSTEOLYSIS; PATHOLOGIC FRACTURE; PRIORITY JOURNAL;

ACID PHOSPHATASE; AGED; ANTINEOPLASTIC AGENTS; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; BONE RESORPTION; COLLAGEN; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; HUMANS; INTERLEUKIN-6; ISOENZYMES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOGENESIS; PEPTIDES;

EID: 19244365106     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2003.02823.x     Document Type: Article

References (35)

1. BERENSON JR. New advances in the biology and treatment of myeloma bone disease. Semin Hematol 2001;38:15-20.
2. ANDERSON KC, LUST JA. Role of cytokines in multiple myeloma. Semin Hematol 1999;36:14-20.
3. SUDA T, NAKAMURA I, JIMI E, TAKAHASHI N. Regulation of osteoclast function. J Bone Miner Res 1997;12:869-879.
4. SHIPMAN CM, ROGERS MJ, APPERLEY JF, RUSSELL RG, CROUCHER PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997;98:665-672.
5. TASSONE P, FORCINITI S, GALEA E, et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000;14:841-844.
6. DERENNE S, AMIOT M, BARILLE S, et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 1999;14:2048-2056.
7. KUNZMANN V, BAUER E, FEURLE J, WEISSINGER F, TONY HP, WILHELM M. Stimulation of γδT-cells by aminobishosphonates and induction of anti-plasma cell activity in multiple myeloma. Blood 2000;96:384-392.
8. BERENSON JR, LICHTENSTEIN A, PORTER L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996;334:488-493.
9. BERENSON JR, LICHTENSTEIN A, PORTER L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998;16:593-602.
10. TERPOS E, PALERMOS J, TSIONOS K, et al. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. Eur J Haematol 2000;65:331-336.
11. TERPOS E, PALERMOS J, VINIOU N, VAIOPOULOS G, MELETIS J, YATAGANAS X. Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment. Calcif Tissue Int 2001;68:285-290.
12. DOOLEY M, BALFOUR JA. Ibandronate. Drugs 1999;57:101-110.
13. LORUSSO P. Analysis of skeletal-related events in breast cancer and response to therapy. Semin Oncol 2001;28:22-27.
14. CRUZ JC, ALSINA M, CRAIG F, et al. Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma. Exp Hematol 2001;29:441-447.
15. DALLAS SL, GARRETT IR, OYAJOBI BO, et al. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood 1999;93:1697-1706.
16. SHIPMAN CM, VANDERKERKEN K, ROGERS MJ, et al. The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma. Br J Haematol 2000;111:283-286.
17. MENSSEN HD, SAKALOVA A, FONTANA A, et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 2002;20:2353-2359.
18. ABILDGAARD N, GLERUP H, RUNGBY J, et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol 2000;64:121-129.
19. FONSECA R, TRENDLE MC, LEONG T, et al. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol 2000;109:24-29.
20. HALLEEN JM, ALATALO SL, SUOMINEN H, CHENG S, JANCKILA AJ, VAANANEN HK. Tartrate-resistant acid phosphatase 5b. a novel serum marker of bone resorption. J Bone Miner Res 2000;15:1337-1345.
21. JANCKILA AJ, TAKAHASHI K, SUN SZ, YAM LT. Tartrate-resistant acid phosphatase isoform 5b as a serum marker of osteoclastic activity. Clin Chem 2001;47:74-80.
22. HALLEEN JM, ALATALO SL, JANCKILA AJ, WOITGE HW, SEIBEL MJ, VAANANEN HK. Serum tartrate-resistant acid phosphatase 5b: is a specific and sensitive marker of bone resorption. Clin Chem 2001;47:597-600.
23. WOITGE HW, HORN E, KECK AV, AULER B, SEIBEL MJ, PECHERSTORFER M. Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis. Clin Chem 2001;47:686-693.
24. BARLOGIE B, SMITH L, ALEXANIAN R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;310:1353-1356.
25. BLADE J, SAMSON D, REECE D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee EBMT. Br J Haematol 1998;102:1115-1123.
26. RALSTON SH, THIEBAUD D, HERRMANN Z, et al. Dose - response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer 1997;75:295-300.
27. ROSEN HN, MOSES AC, GARBER J, ROSS DS, LEE SL, GREENSPAN SL. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif Tissue Int 1998;63:363-368.
28. ROODMAN GD. Cell biology of the osteoclast. Exp Hematol 1999;27:1229-1241.
29. ZERVAS K, POULI A, PERIFANIS V, et al. Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group. Eur J Haematol 1996;57:142-148.
30. TERPOS E, APPERLEY JF, SAMSON D, RAHEMTULLA A. Management of multiple myeloma. Haema 2002;5:24-38.
31. GOODMAN GR, DISSANAYAKE IR, GORODETSKY E, et al. Interferon-alpha, unlike interferon-gamma, does not cause bone loss in the rat. Bone 1999;25:459-463.
32. TSUDA-FUTAMI E, SHIOI A, JONO S, INABA M, NISHIZAWA Y, MORII H. Lymphoblastoid interferon-alpha downregulates parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor expression in human osteoblastic cells (Saos-2). Bone 1998;23:205-211.
33. SAVAGE AD, BELSON DJ, VESCIO RA, LICHTENSTEIN A, BERENSON J. Pamidronate reduces IL-6 production by bone marrow stroma from multiple myeloma patients. Blood 1996;88:105a [abstract].
34. PLOTKIN LI, WEINSTEIN RS, PARFITT AM, ROBERSON PK, MANOLAGAS SC, BELLIDO T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999;104:1363-1374.
35. ABILDGAARD N, RUNGBY J, GLERUP H, et al. Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. Eur J Haematol 1998;61:128-134.